Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms
- PMID: 36924777
- DOI: 10.1016/S0140-6736(23)00353-7
Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms
Conflict of interest statement
I declare that I am a committee member of the Medicines and Healthcare Products Regulatory Agency Medicines for Women's Health Expert Advisory Group (offered meeting attendance fee but not claimed).
Comment on
-
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.Lancet. 2023 Apr 1;401(10382):1091-1102. doi: 10.1016/S0140-6736(23)00085-5. Epub 2023 Mar 13. Lancet. 2023. PMID: 36924778 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources